Show simple item record

dc.contributor.authorLeucht, Stefan
dc.contributor.authorKissling, Werner
dc.contributor.authorMcGrath, John
dc.date.accessioned2017-05-03T16:58:19Z
dc.date.available2017-05-03T16:58:19Z
dc.date.issued2004
dc.date.modified2010-02-09T05:28:30Z
dc.identifier.issn01606689
dc.identifier.urihttp://hdl.handle.net/10072/28687
dc.description.abstractBACKGROUND: Clinicians frequently use lithium to augment antipsychotic medication in schizophrenia. Therefore, we undertook a systematic review and meta-analysis of the use of lithium in the treatment of schizophrenia. DATA SOURCES AND STUDY SELECTION: Randomized controlled trials examining lithium (as a sole or an adjunctive compound) in participants with schizophrenia or related disorders were searched in the register of the Cochrane Schizophrenia Group. No language restrictions were applied. The Boolean phrase [lithium* or lithicarb or eskalith or lithobid or lithane or cibalith-s or quilonum or hypnorex] was used to locate articles. The search strategy initially identified 90 references. The authors of the included studies were contacted to obtain original patient data. The data were combined in a meta-analysis. The main outcome parameters were the number of patients with a clinically significant response and the number of patients leaving the studies early. RESULTS: The meta-analysis includes 20 studies (N = 611). The evidence shows that lithium as a sole agent is ineffective in the treatment of schizophrenia. Eleven trials examined the augmentation of antipsychotics with lithium. More patients who received lithium augmentation than those who received antipsychotics alone were classified as responders. However, the superiority was not consistent across different response thresholds, and when patients with prominent affective symptoms were excluded from the analysis, the advantage of lithium augmentation was not significant (p =.07). Significantly more patients taking lithium left the trials early, suggesting a lower acceptability of lithium augmentation compared with that of taking antipsychotics alone. CONCLUSION: Despite some evidence in favor of lithium augmentation, the overall results are inconclusive. A large trial of lithium augmentation of antipsychotic medications will be required in order to detect a benefit of small effect size in patients with schizophrenia who lack affective symptoms.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherPhysicians Postgraduate Press, Inc.
dc.publisher.placeUS
dc.publisher.urihttp://www.ncbi.nlm.nih.gov/pubmed/15003070
dc.relation.ispartofpagefrom177
dc.relation.ispartofpageto186
dc.relation.ispartofissue2
dc.relation.ispartofjournalJournal of Clinical Psychiatry
dc.relation.ispartofvolume65
dc.subject.fieldofresearchPsychiatry (incl. Psychotherapy)
dc.subject.fieldofresearchMedical and Health Sciences
dc.subject.fieldofresearchPsychology and Cognitive Sciences
dc.subject.fieldofresearchcode110319
dc.subject.fieldofresearchcode11
dc.subject.fieldofresearchcode17
dc.titleLithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.date.issued2004
gro.hasfulltextNo Full Text
gro.griffith.authorMcGrath, John J.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record